Policy brief — Ethiopian Organization for Cancer Prevention and Research
Ethiopian health spending was US$34.80 a head in 2023, 46% of it paid out of pocket (WHO Global Health Observatory (opens in a new tab); the underlying value is 46.27%, set out under THE EVIDENCE below). Radiotherapy capacity, last recorded in 2021, was 0.09 units per million people (indicator DEVICES22).
THE ISSUE
A cancer diagnosis in Ethiopia meets a system in which about half of all health spending is made by households at the point of care. The UHC service coverage index stood at 33 in 2023, up from 13 in 2000. The most recent capacity figures date from 2021.
THE EVIDENCE
Ethiopia’s estimated cancer burden for 2024 was 79,239 new cases and 46,841 deaths (opens in a new tab), with 142,431 alive within five years of a diagnosis; breast, cervical and colorectal were the three most common. On WHO’s 2026 fact sheet, roughly 38% of cancers worldwide (opens in a new tab) could be prevented by acting on risk factors already known.
Health financing, 2023 (opens in a new tab) (WHO Global Health Observatory, indicators GHED_CHE_pc_US_SHA2011, GHED_OOPSCHE_SHA2011 and GHED_OOP_pc_US_SHA2011): current health expenditure US$34.80 per capita; out-of-pocket 46.27% of that, or US$16.10 per capita; government health expenditure US$7.63; external financing US$9.35. The UHC service coverage index was 33, the non-communicable disease sub-index 73. GHO records UHC legislation as not passed, reference year 2017.
Service capacity, 2021. Radiotherapy units: 0.09 per million population (indicator DEVICES22) — against a population of about 132 million, on the order of a dozen machines nationally — a CPR – Ethiopia calculation from those two figures, not a published count. Cancer surgery, radiotherapy, pathology laboratories, an operational cancer plan and oral morphine are reported available in the public sector; palliative care is reported unavailable in primary health care and in community settings.
Workforce, 2024 (WHO Global Health Observatory, National Health Workforce Accounts). Medical doctors: 20,593, or 1.56 per 10,000 population (indicators HWF_0002, HWF_0001). Nursing and midwifery personnel: 143,270, or 10.85 per 10,000 (HWF_0007, HWF_0006). No headcount exists for oncologists, radiation oncologists, medical physicists or pathologists.
Survival. No Ethiopian cancer survival figure is used in this brief. WHO’s Global Health Observatory carries a modelled breast cancer value for Ethiopia under indicator CANCERSURVIVAL_BREASTCANCER, but its time dimension is the diagnosis window 2017–2021 rather than a calendar year, its data source field is empty, and the same indicator returns a value for all 47 WHO African Region member states, several of which operate no cancer registry. IARC’s SURVCAN-3 (opens in a new tab) holds a contribution from the Addis Ababa registry, delivered inside a web application rather than through a queryable interface and covering one city rather than the country. Neither is a national population-based survival measurement, so neither is published here.
Prevention coverage has been rising: infant hepatitis B vaccination reached 81% in 2025, WHO’s estimate of HPV vaccination coverage of the 9–14 target cohort was 51% in 2025 (Global Health Observatory, indicator SDGHPVRECEIVED), against Ethiopia’s own administrative reporting of 96.0% first dose for the same year (HPV_FEM1); both sit in WHO systems, the gap is unexplained in any source used here, and neither is adopted. The capacity indicators carry 2021 as their reference year, with no series behind them.
AREAS FOR CONSIDERATION
The out-of-pocket figures — 46.27% of health spending, US$16.10 per person in 2023 (GHED_OOPSCHE_SHA2011, GHED_OOP_pc_US_SHA2011) — are averages across the whole population, only a small part of which is treated for cancer in a given year, so they do not describe what a cancer-affected household pays; a direct measurement would replace them.
WHO’s record shows UHC legislation not passed as of the 2017 reference year, with no later value. What is covered and who pays is settled by that instrument, and its absence is why the benefit position for cancer — pre-cancer treatment, hepatitis B antivirals, pathology, radiotherapy — cannot be stated.
The capacity record is a rate per million from 2021 and nothing else. Machines, laboratories and specialist headcounts sit in Ministry systems, unpublished; an inventory by region would show whether new investment adds capacity or duplicates it. Oral morphine was reported available in 2021 while palliative care was not — a medicine without a service.
Sources disagree on whether Ethiopia has a population-based cancer registry. Ethiopia reported to WHO in 2021 that one exists (Global Health Observatory, indicator NCD_CCS_PBCR). It is absent from IARC’s Cancer Incidence in Five Continents and from Cancer Over Time, its only public expression a survival dataset inside a web application. The two positions have not been reconciled in any published source, and whether the registry publishes governs what the figures here can be checked against.
WHAT WE DO NOT KNOW
What an Ethiopian household pays for cancer treatment is not documented in any source consulted — a biopsy, pathology, a course of radiotherapy, the travel to reach one of a few centres. Nor is the share of cancer-affected households facing catastrophic expenditure.
How many radiotherapy machines exist is not published; the available figure is a rate per million from 2021, from which a count can only be approximated. The oncology workforce is not counted, though doctors and nurses are.
The service availability answers all carry 2021 as their reference year, and the financing figures 2023. The UHC index of 33 measures service coverage, not financial protection.
Nothing is subnational, so regional variation in burden, screening access or capacity cannot be shown. Nor is there a trend line: WHO’s site-specific cancer mortality series stop at 2004.
Every incidence and mortality figure here is a model output rather than a count — incidence extrapolated from a subnational registry, mortality from modelled ratios. Whether a national population-based registry exists is itself disputed between Ethiopia’s own report to WHO and IARC’s registry series, as set out above.